WXXWY WUXI BIOLGCS ADR
- 3.580
- -0.380-9.60%
WUXI BIOLGCS ADR News
Intraday Overview | Tech Index rose more than 1%, and TechNet stocks were trending strongly. Bilibili rose more than 6%; Tencent Music rose more than 9% after its performance
Technology Network stocks rose collectively, with Bilibili up more than 6%, Kuaishou and Xiaomi Group up more than 3%; auto stocks improved, Great Wall Motor rose more than 7%, NIO rose nearly 6%, and Zero Sports Auto rose nearly 5%.
Big Bank Rating | Jefferies: The upward potential of Pharmaceutical Biotech is greater than the downward potential rating “buy”
Glonghui, May 14 | Jefferies released a report saying that the current stock price of HK$14.7 for Pharmaceutical Biotech means that it only values existing non-US contracts, that is, it does not value existing US contracts, nor does it value new contracts in any region in the future. As unresolved issues will be resolved, the situation is even more clear. The bank believes that the upward potential of Yao Ming Biotech is greater than the downside potential, and that the company is the only large CRO/CDMO company with a market account ratio of only 1.4 times, while the price-earnings ratio of domestic peers is 2 to 3 times, and global peers are 4 to 5 times higher. The bank's target price for Medicinal Biotech was reduced from HK$53
The CXO sector of the Hong Kong stock market showed positive performance, Pharmaco-Ming Kangde rose more than 7%
Glonghui, May 14 | Yao Ming Kangde rose more than 7%, Pharmaceutical Biotech rose nearly 6%, and Cansino Biotech and Zhaoyan New Pharmaceutical followed suit.
Express News | Galaxy Securities: Judging from the pace of the industry's revenue growth rate, the first quarter of 2024 is expected to be the lowest point in the pharmaceutical industry in the whole year
May 13 Repurchase Collection | HSBC Holdings, Hang Seng Bank, etc. bought back one after another, of which HSBC Holdings spent HK$217 million
According to HKEx disclosure documents on May 14, $HSBC Holdings (00005.HK) $ and $Hang Seng Bank (00011.HK) $ repurchased shares. ① $HSBC Holdings (00005.HK) $ repurchased 3.1976 million common shares on May 10, involving an amount of HK$217 million. The repurchase price per share ranged from HK$68.15 to HK$67.8. ② $Hang Seng Bank (00011.HK) $ repurchased 300,000 common shares on May 13, involving an amount of HK$32.698,700. The repurchase price per share ranged from HK$109.4 to HK$10
Featured announcements | Tencent Music's adjusted net profit increased by 23.9%; King's Rui: Legendary Biotech's net loss narrowed
China Life Insurance: The cumulative original premium income for the first 4 months was about 371.2 billion yuan, an increase of 3.9% over the previous year; China Resources Land: The cumulative contract sales amount for the first 4 months was approximately RMB 72.0 billion.
Pharmaceutical Biotech (02269) spent HK$31.967 million to buy back 2.261,000 shares on May 13
Pharmaceutical Biotech (02269) issued an announcement to spend HK$31.967 million on May 13, 2024 to repurchase 2...
Zhitong Hong Kong Stock Connect Active Trading | May 13
On May 13, 2024, Yao Ming Biotech (02269.HK), CNOOC (00883.HK), and Tencent Holdings (00700.HK) ranked in the top 3 of Shanghai-Hong Kong Stock Connect (southbound) turnover, with turnover values of RMB 2,052 billion, RMB 1,959 billion, and RMB 1,888 billion respectively; Yingfu Fund (02800.HK), Pharmaceutical Biotech (02269.HK), and Tencent Holdings (00700.HK) ranked in the top 3 trading volume of Shenzhen-Hong Kong Stock Connect (Southbound) $1,814 million and 13.26, respectively 100 million yuan, 13.16 billion
A quick look at the Hong Kong market | The three major indices have risen one after another. Technology Network stocks and power stocks are popular. Bilibili has risen more than 6%, and Huadian International has risen nearly 8%
Biotech stocks had mixed ups and downs. Pharmaceutical and Ming Union fell%, and Jinxin Fertility rose%; shipping stocks rose, with Dongfang Overseas International, COSCO Marine Control, and COSCO Marine Energy up nearly 6%.
Intraday quick overview | The Science Index rose more than 1% to reach the 4,000 mark; port transport stocks were strong, and COSCO Marine Control rose more than 6%
Water stocks soared across the board. China Water Services rose more than 9%, Beijing Water Group rose more than 8%; high-speed rail infrastructure stocks collectively rallied, CRRC rose more than 9%, and Times Electric rose nearly 7%.
“Pharmacovigilance”, open high and walk low
Glonghui, May 13 | Hong Kong stocks opened high and went low, and Pharmaceutical Kant erased gains. Previously, it had risen by more than 15%; Yao Ming Biotech fell more than 7%, and had previously risen by more than 6%.
Shares of Yao Ming Kang De and Pharmaceutical Biotech rose
Shares of Yao Ming Kang De and Pharmaceutical Biotech rose
Hong Kong stocks opened, the Hang Seng Index fell 0.31%, and the Science Index opened down 0.94%. Pharmaceutical stocks generally rose, Pharma Ming Kangde rose nearly 15%, and Pharmaceutical Biotech rose nearly 8%.
Hong Kong stocks opened, the Hang Seng Index fell 0.31%, and the Science Index opened down 0.94%. Pharmaceutical stocks generally rose, Pharma Ming Kangde rose nearly 15%, and Pharmaceutical Biotech rose nearly 8%.
The medical news is huge! Will Pharmacokinetics usher in a turning point? US pharmaceutical company contract exemption or extension for 8 years
Industry insiders believe that 8 years is enough time for relevant companies to adapt, and the implementation of this greatest uncertainty can also have a positive impact on related companies.
Hong Kong Stock Afternoon Review | The three major indices rose sharply, domestic housing stocks and biotech stocks strengthened, Shimao Group rose more than 42%, and Ziding Pharmaceutical rose nearly 17%
Science and network stocks generally rose; Meituan rose more than 4%, and Bilibili rose nearly 3%; shipping stocks generally rose, with COSCO Maritime Control rising by more than 6%, and Orient Overseas International rising more than 5%.
Changes in Hong Kong stocks | Pharmaceutical Biotech (02269) rose more than 5%, leading the CRO concept financing environment, which is expected to improve the market and continue to monitor the progress of the Aesthetic Biology Act
CRO concept stocks generally rose in early trading. As of press release, Pharmaceuticals (02269) rose 4.67% to HK$14.78; Kanglong Chemical (03759) rose 4.15% to HK$10.28; Pharmaceuticals (02359) rose 3.02% to HK$37.5; and Tiger Pharmaceuticals (03347) rose 2.58% to HK$35.8.
Big Bank Ratings | Jefferies: From the perspective of market accounts, Yao Ming Biotech is currently at an inflection point rating “buying”
Glonghui, May 9 | Jefferies released a report saying that from the perspective of market accounts, Yao Ming Biotech is currently at an inflection point, and it is believed that its risk and reward curves tend to rise more than decline. The bank gave it a “buy” rating, with a target price of HK$53. Jefferies pointed out that investors are reaching consensus on the geopolitical issues faced by Pharmacovigilance. As the US Biological Act progresses, in particular, how to handle existing contracts will become more clear. Jeffrey explained that investors currently assume that the bill will be passed in some form; the bill should not be as severe as it seems, and they estimate that new projects from Yao Ming Biotech and even its Chinese counterpart will be in the next 3 to
The Hong Kong stock CXO concept fluctuated and strengthened, and Pharmaceutical Biotech rose more than 5%
The CXO concept of Hong Kong stocks fluctuated and strengthened. Yao Ming Biotech rose more than 5%, Kanglong Chemical and Pharmaceutical Kangde rose more than 4%, and Kingsley Biotech and Zhaoyan Pharmaceutical followed suit.
The biomedical sector of Hong Kong stocks strengthened, and BaiGene rose more than 5%
Glonghui, May 9 | BeiGene's increase extended to more than 5%, Pharmaceutical Biotech and Rongchang Biotech rose nearly 3%, and Cansino Biotech rose more than 1%.
Research and Development | China Merchants Securities: Drastic reduction in the target price of Pharmaceutical Biotech to HK$13, downgrading the rating to “neutral”
Glonghui, May 8 | China Merchants Securities issued a report, arguing that the hawkish monetary policy of the Federal Reserve will slow down the recovery of drug development and manufacturing (CDMO) performance in the current fiscal year. It is expected that the possibility that Yao Ming Biotech's revenue will increase by medium to high units in this fiscal year will decrease, so its target price was drastically lowered from HK$45 to HK$13, and the rating was downgraded from “increase in holdings” to “neutral”. The bank lowered Yao Ming Biotech's revenue and adjusted net profit forecasts for the current fiscal year by 12% and 17%, respectively, to reflect a further slowdown in the company's overall revenue growth. According to China Merchants Securities, downgrading Yao Ming Biotech this time is counterproductive
Analysis
Price Target
No Data
